<DOC>
	<DOCNO>NCT02359058</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability ramucirumab Japanese participant advanced stomach cancer receive chemotherapy . Participants take ramucirumab combination anti-cancer drug .</brief_summary>
	<brief_title>A Study Ramucirumab Combination Therapy Japanese Participants Who Have Advanced Stomach Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>A histopathologically cytologically confirm diagnosis gastric GEJ adenocarcinoma metastatic locally advanced unresectable . A participant esophageal cancer eligible . Not receive prior firstline systemic chemotherapy locally advance unresectable and/or metastatic disease . Participants whose disease progress &gt; 6 month follow last dose systemic treatment adjuvant/neoadjuvant set eligible . Measurable nonmeasurable , evaluable , disease , determine use guideline Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.1 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 time enrollment . The participant adequate organ function . Resolution Grade ≤1 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ; version [ v ] 4.03 ) clinically significant toxic effect prior locoregional therapy , surgery , anticancer . Female participant childbearing potential must negative serum urinary pregnancy . Have estimate life expectancy ≥12 week judgment investigator . A significant bleeding disorder , vasculitis , significant bleeding episode gastrointestinal tract within 12 week prior enrollment . Uncontrolled arterial hypertension , despite standard medical management . A serious nonhealing wound peptic ulcer bone fracture enrollment . Undergone major surgery within 28 day prior enrollment , subcutaneous venous access device ( reservoir ) placement within 7 day prior enrollment . Radiation therapy within 14 day prior enrollment . Received previous systemic therapy ( include investigational agent ) target VEGF ( vascular endothelial growth factor ) VEGF receptor signal pathway . Cirrhosis level ChildPugh B ( bad ) ; cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . A serious illness medical condition ( ) . Pregnant breastfeeding . Dysphagia oral medication . Known allergy hypersensitivity study treatment . Human epidermal growth factor receptor ( HER ) 2 status positive . Received treatment within 28 day initial dose study drug investigational product nonapproved use drug device .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>